Archives of Obesity and Metabolism (비만대사연구학술지)

The Study of Obesity and Metabolic Syndrome, KAFM (대한가정의학회 비만대사증후군연구회)
권호 표지
DOI QR코드

DOI QR Code

Two Cases of Obesity Treatment Using Liraglutide 3 mg with Intensive Behavioral Changes in Morbidly Obese Patients with Major Depressive Disorder

주요우울증을 동반한 고도비만 환자에 대한 행동요법을 병행한 리라글루티드 치료의 2예

  • Ko, Hae-Jin (Department of Family Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital)
  • 고혜진 (경북대학교 의과대학 경북대학교병원 가정의학과)
  • Received : 2022.05.03
  • Accepted : 2022.06.15
  • Published : 2022.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Obesity is a chronic disease associated with severe complications. A major complication of obesity is depression, which can worsen obesity and vice versa. In addition, most antidepressants or antipsychotics cause weight gain, and the relationship between obesity and depression is clinically critical. However, treatment of obese patients with major depressive disorder is complicated. Bariatric physicians should provide appropriate behavioral interventions alongside pharmacological treatment, considering psychiatric symptoms, drug side effects, and drug interactions. Two successful cases of moderate-to-severe obese patients with major depressive disorder who had been treated for obesity using behavioral intervention therapy along with liraglutide will be discussed. This report highlights the safety and efficacy of liraglutide treatment of obesity in patients with depression who take antidepressants and antipsychotics.

Keywords

References

  1. Burki T. European Commission classifies obesity as a chronic disease. Lancet Diabetes Endocrinol 2021;9:418.
  2. Nam GE, Kim YH, Han K, Jung JH, Rhee EJ, Lee WY. Obesity fact sheet in Korea, 2020: prevalence of obesity by obesity class from 2009 to 2018. J Obes Metab Syndr 2021;30:141-8. https://doi.org/10.7570/jomes21056
  3. Kim BY, Kang SM, Kang JH, et al. 2020 Korean Society for the Study of Obesity guidelines for the management of obesity in Korea. J Obes Metab Syndr 2021;30:81-92. https://doi.org/10.7570/jomes21022
  4. Kim BY, Kang SM, Kang JH, et al. Current long-term pharmacotherapies for the management of obesity. J Obes Metab Syndr 2020;29:99-109. https://doi.org/10.7570/jomes20010
  5. Fruh SM. Obesity: risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc Nurse Pract 2017;29:S3-14.
  6. Holt RIG. Association between antipsychotic medication use and diabetes. Curr Diab Rep 2019;19:96. https://doi.org/10.1007/s11892-019-1220-8
  7. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22. https://doi.org/10.1056/NEJMoa1411892
  8. O'Neil PM, Aroda VR, Astrup A, et al. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab 2017;19:1529-36. https://doi.org/10.1111/dom.12963
  9. Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry 2017;74:719-28. https://doi.org/10.1001/jamapsychiatry.2017.1220
  10. Camkurt MA, Lavagnino L, Zhang XY, Teixeira AL. Liraglutide for psychiatric disorders: clinical evidence and challenges. Horm Mol Biol Clin Investig 2018;36:20180031. https://doi.org/10.1515/hmbci-2018-0031
  11. Weina H, Yuhu N, Christian H, Birong L, Feiyu S, Le W. Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity. Brain Res 2018;1694:55-62. https://doi.org/10.1016/j.brainres.2018.04.031
  12. U.S. Food and Drug Administration. SAXENDA (liraglutide [rDNA origin] injection), solution for subcutaneous use [Internet]. U.S. Food and Drug Administration. 2014 [cited 2022 May 3]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf